Welcome to AMYPAD!

We were a collaborative research initiative aiming to improve the understanding, diagnosis and management of Alzheimer’s disease through the utilisation of ß-amyloid PET imaging.

The Amyloid imaging to prevent Alzheimer’s disease (AMYPAD) initiative aimed to:

 💡 You can now make a formal request to access our data!

 

→ Access data

 

→ Our papers

 

Homepage Image Neuraceq™ (left) and Vizamyl™ (right). Upper images: amyloid negative scans. Lower images: amyloid positive scans.
Latest News
AMYPAD at EU-MIND Congress
AMYPAD at EU-MIND Congress 26 Sep 2024 This landmark event was the first European congress dedicated to neuroimaging in neurodegenerative diseases......
AMYPAD at AAIC2024
AMYPAD at AAIC2024 05 Aug 2024 An educational session at AAIC 2024 was chaired by Gill Farrar and Andrew Stephens......
EMA endorses Centiloid method for the measurement of brain amyloid burden
EMA endorses Centiloid method for the measurement of brain amyloid burden 16 Jul 2024 The Centiloid method received a Biomarker Qualification Opinion from EMA....
"We would hope that the direct results of the project are useful about our thinking of when amyloid deposition starts and when it's clinically relevant. But what is even more important is that the consortium that we formed, started collaborating on things that go well beyond the initial goals of AMYPAD. And actually, we should further integrate AMYPAD, EPAD and all the European cohorts that are now collaborating and joining forces in analysis of PET/MRI scans, imaging, biomarker but also genetic data. It is something of great value and will contribute to the future of all samples, definitely in Europe and hopefully also globally. ” Frederik Barkhof
Frederik Barkhof

AMYPAD Project Coordinator and Professor of Neuroradiology at VU University Medical Centre, Amsterdam and at University College London.